MARKET

ADVM

ADVM

Adverum Biotech
NASDAQ
14.66
+0.51
+3.60%
Closed 16:06 03/27 EDT
OPEN
14.16
PREV CLOSE
14.15
HIGH
15.16
LOW
13.73
VOLUME
166.90K
TURNOVER
0
52 WEEK HIGH
29.70
52 WEEK LOW
6.81
MARKET CAP
304.27M
P/E (TTM)
-1.2615
1D
5D
1M
3M
1Y
5Y
Down -29.25% in 4 Weeks, Here's Why You Should You Buy the Dip in Adverum Biotechnologies (ADVM)
NASDAQ · 1d ago
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 2d ago
Weekly Report: what happened at ADVM last week (0318-0322)?
Weekly Report · 3d ago
Adverum Biotechnologies files for $200M mixed securities shelf
Adverum Biotechnologies files for $200M mixed securities shelf. The company filed a prospectus related to the offer and sell up to an aggregate amount of $200,000,000. Adverum's stock is down 2.7% in pre-market trading.
Seeking Alpha · 6d ago
Positive Outlook for Adverum Biotechnologies with Upcoming Ixo-vec Milestones and Strong Financial Position
TipRanks · 03/21 06:46
Why Lifecore Biomedical Shares Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of Lifecore Biomedical, Inc. Dipped 31.7% to $4.91 on Wednesday. ETAO International Co., Ltd. Shares shot up 111.5% after the company announced a reverse stock split. NuScale Power Corporation shares tumbled around 35% after spiking 17% on Tuesday.
Benzinga · 03/20 18:03
Brexit Uncertainty: Navigating New Risks and Regulatory Hurdles for Adverum Biotechnologies
TipRanks · 03/20 06:00
Ocular Therapeutics' Impressive Surge: A Strategic Insight
Ocular Therapeutics' stock has surged 184% in six months, driven by promising clinical assets in eye disease treatments. The company is developing clinical assets for chronic ailments of the eye. Ocular's Paxtrava faces tough competition and logistical challenges in glaucoma treatment. Investment recommendation: Hold OCUL stock.
Seeking Alpha · 03/19 20:04
More
About ADVM
Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company. The Company discovers and develops gene therapy product candidates that provides durable efficacy by inducing sustained expression of a therapeutic protein. Its lead product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable levels of aflibercept associated with a sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) IVT injections. Ixo-vec is being developed for the treatment of patients with wet age-related macular degeneration. Its second product candidate, ADVM-062 (AAV.7m8-L-opsin), is a gene therapy product candidate being developed to treat patients suffering from blue cone monochromacy (BCM) via a single IVT injection. It also developing an early-stage pipeline of gene therapy programs.

Webull offers Adverum Biotechnologies Inc stock information, including NASDAQ: ADVM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ADVM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ADVM stock methods without spending real money on the virtual paper trading platform.